Update on Commercial Terms for the Proposed Merger with MAP

• Microba shareholders to hold 60% of GSS upon merger
• Existing GSS shareholders to hold 40% of GSS
• All other terms remain unchanged

Genetic Signatures Limited (ASX: GSS) and Microba Life Sciences Limited (ASX: MAP) have agreed on revised terms for their proposed merger. Under the new terms, Microba shareholders will hold 60% of GSS on implementation, down from the previously agreed 67%. Existing GSS shareholders will hold 40%, up from the previous 33%. All other terms of the proposed merger remain unchanged. The revised terms will be detailed in an addendum to the Notice of AGM, which is currently with ASX for review.

Microba shareholders to hold 60% of GSS upon merger, existing GSS shareholders to hold 40%

The merger is progressing as planned, subject to shareholder and court approval, with the revised terms expected to be finalized soon.